本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：600267 证券简称：海正药业 公告编号：临 2026-14 号 浙江海正药业股份有限公司 关于 2021 年限制性股票激励计划预留授予部分第三个 解除限售期解除限售暨股票上市公告 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 57.225 万股。 本次股票上市流通总数为57.225 万股。 本次股票上市流通日期为2026 年 2 月 24 日。 浙江海正药业股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日召开第十 届董事会第十三次会议，审议通过了《关于 2021 年限制性股票激励计划预留授予 部分第三个解除限售期解除限售条件成就的议案》，该议案已经董事会薪酬与考核 委员会审议通过。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《浙江海正药业股份有限公司 2021 年限制性股票激励计划》（以下简称"《激励计 划》"）等相关规定及公司 2021 年第二次临时股东大会对董事会的授权，公司 2021 年 ...

证券之星消息，2月10日宠物经济板块较上一交易日上涨0.25%，汇隆新材领涨。当日上证指数报收于 4128.37，上涨0.13%。深证成指报收于14210.63，上涨0.02%。宠物经济板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300760 迈瑞医疗 | | 4580.35万 | 4.66% | -1269.74万 | -1.29% | -3310.61万 | -3.37% | | 002862 | 实丰文化 | 2147.29万 | 14.93% | -882.79万 | -6.14% | -1264.51万 | -8.79% | | 300640 | 德艺文创 | 1986.35万 | 9.90% | -585.77万 | -2.92% | -1400.58万 | -6.98% | | 301057 | 汇隆新材 | 1503.17万 | 9.88% | -862.72万 | -5.6 ...

Group 1 - Crayon Shin-chan Foods announced the acquisition of Qucloud AI HK Limited for HKD 188 million, marking its transition from a traditional jelly manufacturer to an AI-driven data company [2] - The acquisition will be paid entirely in shares, with 20,834,480 shares issued at HKD 3.98 each, totaling approximately HKD 81 million, and a zero-interest convertible bond worth approximately HKD 106 million [2] - The convertible bond, if fully converted, will result in the issuance of about 22.84 million shares, representing 10.46% of the existing share capital [2] Group 2 - Aipu Co., Ltd. plans to acquire 80% of Noah Saint No (Taicang) Biotechnology Co., Ltd. for CNY 360 million, with a total estimated value of the target company at no less than CNY 450 million [3] - The final transaction price will be determined based on due diligence, audit, and valuation results [3] Group 3 - Jinfeng Technology announced plans to acquire 51% stakes in two liquid cooling companies for a total consideration of up to CNY 714 million [4] - The acquisition of both companies is interdependent, meaning both transactions must be completed simultaneously [4] Group 4 - Mingde Bio announced a cash investment of CNY 35.7 million to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd., making it a subsidiary [5] - The acquisition is contingent upon the completion of historical debt agreements and further acquisition of remaining shares based on performance conditions [5] Group 5 - Zhejiang Haizheng Pharmaceutical reached a settlement requiring a cash payment of approximately CNY 129 million and the acquisition of shares from Genius III [7] - This settlement aims to resolve previous arbitration rulings and will increase the company's shareholding in Cayman Daoming [7] Group 6 - Sergio Ramos and Five Eleven Capital Group are advancing their acquisition of Sevilla FC, with a new investment of approximately EUR 450 million [8] - The funds will primarily be used to acquire about 65% of the club's shares, with additional investments being sought to alleviate potential loan pressures [8] Group 7 - Tether's investment division acquired approximately 12% of Goldcom for USD 150 million, integrating its gold stablecoin XAUt into the platform [8] - The partnership aims to facilitate the purchase of physical gold using USDT and USAt in the U.S. market [8] Group 8 - Infineon Technologies announced the acquisition of ams Osram's non-optical analog/mixed-signal sensor product group for EUR 570 million [9] - This acquisition is expected to enhance Infineon's product portfolio and generate approximately EUR 230 million in revenue by 2026 [9]

Core Viewpoint - Haizheng Pharmaceutical announced the approval of the third unlock condition for its 2021 restricted stock incentive plan, allowing 572,250 shares to be released from restrictions, benefiting 66 individuals [2]. Group 1 - The company held its 13th meeting of the 10th Board of Directors on February 5, 2026, to review the proposal regarding the unlock conditions of the restricted stock incentive plan [2]. - The proposal was approved by the Board's Compensation and Assessment Committee and is in accordance with the authorization from the company's second extraordinary general meeting in 2021 [2]. - After completing the procedures for the release of the restricted stock, the company will issue an announcement regarding the release and listing of the stock [2].

Core Viewpoint - The company announced an adjustment to the repurchase price of restricted stock and the cancellation of certain stock options due to changes in eligibility and performance criteria [1] Group 1: Stock Repurchase and Adjustment - The company plans to adjust the repurchase price of reserved restricted stock from 8.56 yuan per share to 8.35 yuan per share [1] - This adjustment follows the completion of the company's 2024 annual equity distribution [1] Group 2: Cancellation of Stock Options - The company intends to cancel a total of 87,000 shares of restricted stock held by seven individuals who no longer qualify for stock incentives and two individuals who did not meet personal performance assessment requirements [1] - This cancellation is in accordance with the company's 2021 restricted stock incentive plan and the authorization from the second extraordinary general meeting of shareholders in 2021 [1]

Group 1 - The company, Haizheng Pharmaceutical, announced that its 13th meeting of the 10th board of directors was held on February 5, 2026, via telecommunication [1] - The meeting reviewed a proposal regarding the adjustment of the repurchase price of restricted stock and the cancellation of certain restricted stocks granted to incentive recipients that have not yet been released from the lock-up period [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2026-11 号 浙江海正药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）于2026年2月5日召开第十 届董事会第十三次会议，审议通过了《关于调整限制性股票回购价格及回购注销 部分激励对象已获授但尚未解除限售的限制性股票的议案》，同意将9名激励对 象持有的已获授但尚未解除限售的87,000股限制性股票进行回购注销，具体详见 2026年2月6日公司登载于《中国证券报》《上海证券报》《证券时报》和上海证 券交易所网站（www.sse.com.cn）上的《浙江海正药业股份有限公司关于调整限 制性股票回购价格及回购注销部分激励对象已获授但尚未解除限售的限制性股 票的公告》（公告编号：临2026-10号）。 回购完毕后，公司将向中国证券登记结算有限责任公司上海分公司申请办理 该部分股票的注销。注销完成后，公司总股本将由1,198,848,196股减少至 1,198,761, ...

证券代码：600267 证券简称：海正药业 公告编号：临 2026-10 号 浙江海正药业股份有限公司 关于调整限制性股票回购价格及回购注销部分激励 对象已获授但尚未解除限售的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 调整限制性股票回购价格： 预留授予限制性股票回购价格由 8.56 元/股调整为 8.35 元/股 本次限制性股票回购注销数量：87,000 股。 浙江海正药业股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日召开第 十届董事会第十三次会议，审议通过了《关于调整限制性股票回购价格及回购注 销部分激励对象已获授但尚未解除限售的限制性股票的议案》，该议案已经董事 会薪酬与考核委员会审议通过。鉴于公司 2024 年年度权益分派实施完毕，根据 《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《浙江海正药业股份 有限公司 2021 年限制性股票激励计划》（以下简称"《激励计划》"或"本次激励 计划"）的相关规定以及公司 2021 年第二次临时股东大会的授权，公司 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2026-12 号 浙江海正药业股份有限公司 关于 2021 年限制性股票激励计划预留授予部分第三 个解除限售期解除限售条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江海正药业股份有限公司（以下简称"公司"）将在办理完毕本次限制 性股票解除限售手续后、股票上市流通前，发布限制性股票解除限售暨上市公告， 敬请投资者注意。 公司于 2026 年 2 月 5 日召开第十届董事会第十三次会议，审议通过了《关 于 2021 年限制性股票激励计划预留授予部分第三个解除限售期解除限售条件成 就的议案》，该议案已经董事会薪酬与考核委员会审议通过。根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）、《浙江海正药业股份有限公司 2021 年限制性股票激励计划》（以下简称"《激励计划》"）等相关规定及公司 2021 年 第二次临时股东大会对董事会的授权，公司 2021 年限制性股票激励计划（以下 简称"本次激励计划"）预留授予部分第三个解除限售 ...

2021 年限制性股票激励计划 调整回购价格、回购注销及解除限售相关事项 上海君澜律师事务所 关于 浙江海正药业股份有限公司 之 法律意见书 二〇二六年二月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于浙江海正药业股份有限公司 2021 年限制性股票激励计划 调整回购价格、回购注销及解除限售相关事项之 法律意见书 致：浙江海正药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江海正药业股份有限公 司（以下简称"公司"或"海正药业"）的委托，根据《上市公司股权激励管 理办法》（以下简称"《管理办法》"）及《浙江海正药业股份有限公司 2021 年限制性股票激励计划》（以下简称"《激励计划》"或"本次激励计划"） 的规定，就海正药业调整本次激励计划回购价格、回购注销部分激励对象已获 授但尚未解除限售的限制性股票及预留授予部分第三个解除限售期解除限售条 件成就（以下简称"本次调整、回购注销及解除限售"）相关事项出具本法律 意见书。 2 上海君澜律师事务所 法律意见书 （三）本所仅就公司本次调整、回购注销及解除限售的相关法律事项发表 意见，而不对公司本次调整、回购注销及解除限售所涉及的标的股权价 ...